Transforming growth factor-beta expression in mouse lung carcinogenesis

Experimental Lung Research

Volumn 24, Issue 4, 1998, Pages 579-593

  Jakowlew, Sonia B ^a   Moody, Terry W ^a   You, Liang ^a,b   Mariano, Jennifer M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

A J mouse; Chemical carcinogenesis; Gene expression; Tumor progression

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER MORTALITY; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DNA SEQUENCE; EPITHELIUM CELL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 0031804499     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149809087387     Document Type: Conference Paper

References (45)

1. Cancer Facts and Figures, 1996. Atlanta, GA: American Cancer Society: 1996: 10.
2. Ginsberg RJ. Multimodality therapy for stage IIIA (N2) lung cancer: an overview. Chest. 1993; 103:356s-359s.
3. Malkinson AM. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res (Suppl). 1992; 52:2670s-2676s.
4. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the K-ras protoonocogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA. 1989; 86:3070-3074.
5. Festing MFW, Yang A, Malkinson AM. At least four genes and sex are associated with susceptibility to urethane-induced pulmonary adenomas in mice. Genet Res. 1994; 64:99-106.
6. Horio Y, Chen A, Rice P, Roth JA, Malkinson AM, Schrump DS. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog. 1996; 17:217-223.
7. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB, eds. Handbook of Experimental Pharmacology. Berlin: Springer; 1990:419-472.
8. Massagure' J, Cheifetz S, Laiho M, Ralph DA. Transforming growth factor-beta. Cancer Surv. 1992; 12:81-103.
9. Chiefetz S, Weatherbee JA, Tsang ML-S, et al. The transforming growth factor-beta system, a complex pattern of cross reactive ligands and receptors. Cell. 1987; 48:409-415.
10. Damstrup, L, Rygaard K, Spang-Thomsen M, Poulson HS. Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2, TGF-beta 3 in human small cell lung cancer cell lines. Br J Cancer. 1993; 1015-1021.
11. Norgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard HP. Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. Br J Cancer. 1994; 69:802-808.
12. Reiss M, Sartorelli A. Regulation of growth and differentiation of human keratinocytes by type β transforming growth factor and epidermal growth factor. Cancer Res. 1987; 47:6705-6709.
13. Geiser A, Burmester J, Webbink R, Roberts A, Sporn M. Inhibition of growth by transforming growth factor-β following fusion of two non-responsive human carcinoma cell lines. J Biol Chem. 1992; 267:2588-2593.
14. Park J, Kim S-J, Bang Y-J, Park J-G, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric carcinoma cells: correlation, with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA. 1994; 91:8772-8776.
15. Markowitz S, Myerhoff L, Cooper M, Vogelstein B. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigeneicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene. J Clin Invest. 1994; 93:1005-1013.
16. Manning A, Williams A, Game S, Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF β): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β. Oncogene. 1991 ; 6:1471-1476.
17. Jakowlew SB, Mathias A, Chung P, Moody TW. Expression of transforming growth factor β ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ. 1995; 6:465-476.
18. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18:5294-5299.
19. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA. 1984; 80:1991-1995.
20. Qian SW, Kondaiah P, Roberts AB, Sporn MB. cDNA cloning by PCR of rat transforming growth factor-β1. Nucleic Acids Res. 1990; 8:3059.
21. Miller DA, Lee A, Pelton RW, Chen EY, Moses HL, Derynck R. Murine transforming growth factor-β2 cDNA sequence and expression in adult tissues and embryos. Mol Endocrinol. 1989; 3:1108-1114.
22. Denhez F, Lafyatis R, Kondaiah P, Roberts AB, Sporn MB. Cloning by polymerase chain reaction of a new mouse TGF-β, TGF-β3. Growth Factors. 1990; 3:1325-1345.
23. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger mRNAs for transforming growth factors alpha and β and the epidermal growth factor receptor by human tumors. Cancer Res. 1987; 47:707-712.
24. Yoshida K, Yokozaki H, Niimoto M, Ito H, Tahara E. Expression of TGF-β and procollagen type I and type III in human gastric carcinomas. Int J Cancer. 1989; 44:394-398.
25. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factor alpha and β1 in renal cell carcinoma. Cancer Res. 1989; 49:6972-6975.
26. Barrett P, Travers M, Luqmani Y, Coombes RC: Transforming growth factors in human breast cancer: clinical correlates. Br J Cancer. 1990; 61:612-617.
27. La Rocca RV, Park JG, Danesi R, Tacca MD, Steinberg SM, Gazdar AF. Pattern of growth factor, proto-oncogene and carcinoembryonic antigen gene expression in human colorectal carcinoma cell lines. Oncology. 1992; 49:209-214.
28. Knabbe C, Klein H, Zugmaier G, Voigt KD. Hormonal regulation of transforming growth factor β-2 expression in human prostate cancer. J Steroid Biochem Mol. Biol. 1993; 47:137-142.
29. Gold LI, Korc M. Expression of transforming growth factor-β1, 2, and 3 mRNA in human cancers. Dig Surg. 1994; 11:150-156.
30. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R. T cell suppressor factor from human glioblastoma cells is a 12.5 kd protein closely related to transforming growth factor-β.EMBO J. 1987; 6:1633-1636.
31. Jakowlew SB, Kondaiah PK, Flanders KC, et al. Increased coordinate expression of growth factor mRNAs accompanies viral transformation of rodent cells. Oncogene Res. 1988; 2:135-148.
32. Anzano MA, Roberts AB, DeLarco JE, et al. Increased secretion of type beta transformation growth factor accompanies viral transformation. Mol Cell Biol. 1985; 5:242-247.
33. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors. 1993; 8:1-9.
34. Raghow R, Postlethwait AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-β increases steady state levels of type I collagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest. 1987; 79:1285-1288.
35. Ignotz RA, Massague' J. Cell adhesion protein receptors as targets for transforming growth factor-β action. Cell. 1987; 51:189-197.
36. Sato Y, Tsuboi R, Lyons R, Moses H, Rilkin DB. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells, and pericytes and smooth muscle cells: a self-regulating system. J. Cell Biol. 1990; 111:757-763.
37. Jennings MT, Maciunas RJ, Carver R, et al. TGF β1 and TGF β2 are potent growth regulators for low grade and malignant gliomas in vitro:evidence in support of an autocrine hypothesis. Int J Cancer. 1991; 49:129-139.
38. Haddow S, Fowlis DJ, Parkinson K, Akhurst RJ, Balmain A. Loss of growth control by TGF-β occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene inactivation. Oncogene. 1991; 6:165-170.
39. Massague' J, Attisano L, Wranna J. The TGF-β family and its composite receptors. Trends Cell Biol. 1994; 4:172-178.
40. Markowitz S, Wang J, Myerhoff L, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 1995; 268:1336-1338.
41. Myerhoff LL, Parsons R, Kim S-J, et al. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995; 55:5545-5547.
42. Parsons R, Myerhoff LL, Liu B, et al. Microsatellite instability and mutations of the TGF-β type II receptor gene in colorectal cancer. Cancer Res. 1995; 55:5548-5550.
43. Garrigue-Antar L, Munoz-Antonia T, Antonia S, Gesmonde J, Vellucci V, Reiss M. Mis-sense mutations of the transforming growth factor β type II receptor in head and neck squamous carcinoma cells. Cancer Res. 1995; 55:3982-3987.
44. Baldwin RL, Friess H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer. 1996; 67:283-288.
45. DeCoteau JF, Knaus PI, Yankelev H, et al. Loss of functional cell surface transforming growth factor β (TGF-β) type I receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc. Nad Acad Sci USA. 1997; 94:5877-5881.